HTB homepage • Conference reports • Articles by subject • Subscribe August 2017 Contents Editorial July/August 2017: Volume 18 Number 7/8 Special reports i-Base 2017 appeal: we need your help…. Supplements HIV Pipeline Report (2017) Fit for Purpose: HIV treatment optimisation for adults and children (2017) Conference reports 9th IAS Conference on HIV Science (IAS 2017) HIV pipeline drugs: IAS 2017 update Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results Reduced-dose darunavir is safe and effective in switch study MK-8591: further compelling early results for both treatment and prevention Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study Preliminary results on dolutegravir use in pregnancy are reassuring Low dose efavirenz (EFV400) can be used during pregnancy Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population Swaziland nearly halves HIV incidence in five years Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U HIV remission news from IAS 2017 Publications launched at IAS 2017 9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris Chewable raltegravir tablets can be crushed and dispersed in liquid for young children Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy Antiretrovirals First dolutegravir-based generic FDC gets FDA tentative approval FDA grant priority review for ibalizumab Hepatitis coinfection UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’ FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US HIV prevention and transmission Controversial PrEP study from NHS England due to start in September PDFs July/August 2017: Volume 18 Number 7/8 HTB homepage • Conference reports • Articles by subject • Subscribe